Haemonetics Corporation $HAE Shares Newly Bought by Vise Technologies Inc.

Vise Technologies Inc. purchased a new stake in shares of Haemonetics Corporation (NYSE:HAE) in the third quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 5,822 shares of the medical instruments supplier’s stock, valued at approximately $613,000.

Several other large investors have also recently made changes to their positions in HAE. VIRGINIA RETIREMENT SYSTEMS ET Al raised its holdings in Haemonetics by 178.6% in the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 11,700 shares of the medical instruments supplier’s stock worth $1,232,000 after acquiring an additional 7,500 shares during the last quarter. VestGen Advisors LLC purchased a new position in shares of Haemonetics in the third quarter worth approximately $2,901,000. SYM FINANCIAL Corp bought a new stake in Haemonetics during the third quarter valued at approximately $216,000. Citizens Financial Group Inc. RI purchased a new stake in Haemonetics during the third quarter valued at approximately $256,000. Finally, Sterling Capital Management LLC raised its position in Haemonetics by 608.1% in the third quarter. Sterling Capital Management LLC now owns 1,487 shares of the medical instruments supplier’s stock worth $157,000 after acquiring an additional 1,277 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Haemonetics Stock Performance

Shares of NYSE:HAE opened at $120.72 on Thursday. Haemonetics Corporation has a 52 week low of $51.00 and a 52 week high of $132.00. The stock has a market capitalization of $5.50 billion, a P/E ratio of 54.13, a PEG ratio of 2.45 and a beta of 0.63. The firm has a fifty day simple moving average of $112.54 and a two-hundred day simple moving average of $80.81. The company has a quick ratio of 1.83, a current ratio of 2.84 and a debt-to-equity ratio of 1.24.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, November 5th. The medical instruments supplier reported $1.35 EPS for the quarter, beating analysts’ consensus estimates of $1.29 by $0.06. The firm had revenue of $357.76 million during the quarter, compared to the consensus estimate of $345.15 million. Haemonetics had a net margin of 7.52% and a return on equity of 27.42%. The firm’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter last year, the firm earned $1.27 EPS. On average, analysts expect that Haemonetics Corporation will post 5.32 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on HAE shares. BTIG Research boosted their price target on Haemonetics from $130.00 to $142.00 and gave the company a “buy” rating in a report on Thursday, November 5th. Mizuho set a $165.00 price objective on shares of Haemonetics in a research note on Thursday, November 5th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haemonetics in a report on Wednesday, November 4th. Raymond James Financial increased their target price on Haemonetics from $105.00 to $125.00 and gave the stock an “outperform” rating in a research report on Thursday, September 3rd. Finally, Robert W. Baird increased their price objective on shares of Haemonetics from $96.00 to $119.00 and gave the company an “outperform” rating in a report on Friday, August 21st. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $126.38.

Haemonetics Company Profile

Haemonetics Corporation is a global medical technology company focused on blood and plasma collection, processing and management. Its products and services are used by plasma collection organizations, blood centers and hospitals. The company provides automated plasma collection systems and related software and supplies, as well as technologies for collecting and processing blood components. Its hospital offerings include devices for surgical blood salvage and tools that help clinicians assess blood clotting and guide transfusion decisions.